This January 2024, we're spotlighting Bruton's tyrosine kinase (BTK) as our Clovertex Target of the ...
Medicine experienced a monumental moment in 2023 with the recognition of BCL11A as the 2023 Cloverte...
Amidst a flurry of big pharma deals, the Muscarinic acetylcholine receptor subtype M4 has emerged as...
This November, we highlight the folate receptor alpha (FRα) as the 'Clovertex Target of the Month'. ...
For October 2023, we have the Human Epidermal growth factor Receptor 3 (HER3) as the 'Clovertex Drug...
September's Clovertex Target of the Month is GPR61 following Pfizer's recent publication concerning ...
In August 2023, the GABAA receptor is highlighted our 'Clovertex Target of the Month' as the drug ta...
For July 2023, we focus our attention on the Adeno-Associated Virus serotype 9 (AAV9) as the 'Clover...
For June 2023, we draw your attention to the Endothelin A Receptor (ETAR) as the 'Clovertex Drug Tar...
For May 2023, we're spotlighting the Glucagon-Like Peptide-2 Receptor (GLP2R) as the 'Clovertex Drug...